Merck (MRK) Current Taxes (2009 - 2026)
Merck (MRK) reported Current Taxes of $3.9 billion for Q1 2026, down 23.84% year-over-year from $5.2 billion in Q1 2025, and down 16.5% quarter-over-quarter from $4.7 billion in Q4 2025.
Merck (MRK) Current Taxes (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Current Taxes data on file, last reported at $3.9 billion in Q1 2026.
- Current Taxes for Q1 2026 came in at $3.9 billion, down 23.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 billion (down 23.84% YoY), and the FY2025 annual result was $4.7 billion, up 20.75% from the prior year.
- Current Taxes retreated to $3.9 billion in Q1 2026 per MRK's latest filing, from $4.7 billion in the prior quarter.
- Over five years, Current Taxes peaked at $5.2 billion in Q1 2025 and troughed at $1.4 billion in Q2 2022.
- A 5-year average of $3.0 billion and a median of $2.6 billion in 2023 frame the typical range for Current Taxes.
- The sharpest annual moves came in 2024 and 2026: Current Taxes jumped 118.58% in 2024, then slipped 23.84% in 2026.
- A 5-year view of Current Taxes shows it stood at $2.0 billion in 2022, then jumped by 33.38% to $2.6 billion in 2023, then surged by 47.75% to $3.9 billion in 2024, then gained by 20.75% to $4.7 billion in 2025, then slipped by 16.5% to $3.9 billion in 2026.
- Business Quant data shows MRK's Current Taxes at $3.9 billion in Q1 2026, $4.7 billion in Q4 2025, and $4.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -748.24 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 1.09 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 3.95 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 3.13 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.95 Bn |
| Dec 31, 2025 | 4.73 Bn |
| Sep 30, 2025 | 4.85 Bn |
| Jun 30, 2025 | 4.16 Bn |
| Mar 31, 2025 | 5.18 Bn |
| Dec 31, 2024 | 3.91 Bn |
| Sep 30, 2024 | 4.33 Bn |
| Jun 30, 2024 | 2.78 Bn |
| Mar 31, 2024 | 2.40 Bn |
| Dec 31, 2023 | 2.65 Bn |
| Sep 30, 2023 | 1.98 Bn |
| Jun 30, 2023 | 1.49 Bn |
| Mar 31, 2023 | 1.87 Bn |
| Dec 31, 2022 | 1.99 Bn |
| Sep 30, 2022 | 1.70 Bn |
| Jun 30, 2022 | 1.44 Bn |
| Mar 31, 2022 | 1.57 Bn |
| Dec 31, 2021 | 1.22 Bn |
| Sep 30, 2021 | 954.00 Mn |
| Jun 30, 2021 | 971.00 Mn |